1,803 patents currently held
128 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
12 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
519
Ending by 2030
Nov 2026
Next term end
1,510
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2028 · High confidence
Also notable
Ends Jun 2027 · High confidence
Also notable
Ends Jan 2035 · High confidence
Antibodies to Human Programmed Death Receptor PD-1
US 8,354,509
The most cited patent in this portfolio, cited by 461 later US patents, top 1% of utility patents granted in 2013 in our data. Protection runs to 2028.
Non-Immunostimulatory Antibody and Compositions Containing the Same
US 7,700,099
Cited by 114 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Tablet Formulation for CGRP Active Compounds
US 10,117,836
Cited by 32 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Nov 14 to 28, 2026 · next Nov 14
- 9 fees due Dec 2 to 30, 2026 · next Dec 2
- 25 fees due Jan 2 to 28, 2027 · next Jan 2
- 22 fees due Feb 4 to 27, 2027 · next Feb 4
- 31 fees due Mar 1 to 29, 2027 · next Mar 1
- 26 fees due Apr 1 to 30, 2027 · next Apr 1
- 23 fees due May 3 to 28, 2027 · next May 3
- 28 fees due Jun 1 to 30, 2027 · next Jun 1
- 35 fees due Jul 5 to 30, 2027 · next Jul 5
- 20 fees due Aug 4 to 25, 2027 · next Aug 4
- 30 fees due Sep 1 to 30, 2027 · next Sep 1
- 20 fees due Oct 5 to 30, 2027 · next Oct 5
- 13 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- 21 of the patents on this record were granted since Aug 16, 2026
- 52 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 1,510 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Antibody Neutralizing Human Respiratory Syncytial Virus | 8 in force | to May 2037 |
| Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | 8 in force | to Sep 2030 |
| Anti-Coagulation Factor XI Antibodies | 6 in force | to Mar 2038 |
| Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists | 6 in force | to Jun 2036 |
| Ceftolozane-Tazobactam Pharmaceutical Compositions | 6 in force | to Nov 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,816,380 | 1-Hydroxycycloalkanecarboxamide Derivatives In force · High confidence | In force | High confidence | |
| US 7,569,592 | Heteroaryl Substituted Pyrazole Modulators of Metabotropic Glutamate RECEPTOR-5 In force · High confidence | In force | High confidence | |
| US 7,625,938 | Substituted Pyrazoles, Compositions Containing Such Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 7,618,985 | Isoquinoline Derivatives held by Merck Sharp & Dohme B.V. In force · High confidence | In force | High confidence | |
| US 8,486,983 | Self-Emulsifying Formulations of Cetp Inhibitors In force · High confidence | In force | High confidence | |
| US 7,528,132 | Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,298,543 | Identification and Application of Antibiotic Synergy In force · High confidence | In force | High confidence | |
| US 7,888,369 | Oxazoloisoquinoline Derivatives as Thrombin Receptor Antagonists In force · High confidence | In force | High confidence | |
| US 7,547,720 | Ophthalmic Compositions for Treating Ocular Hypertension In force · High confidence | In force | High confidence | |
| US 7,709,658 | Process for Synthesizing a Substituted Pyrazole In force · High confidence | In force | High confidence |
Also on record, not counted in the 1,803: 128 patents in force now held by others · 1,686 patents ended · 401 applications pending · 1,237 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.